Standard Cost Of Revenue vs Income Before Tax Analysis

LAB Stock

USD 1.82 0.11 6.43%

Standard Biotools financial indicator trend analysis is much more than just breaking down Standard Biotools prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Standard Biotools is a good investment. Please check the relationship between Standard Biotools Cost Of Revenue and its Income Before Tax accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Standard Biotools Cost Of Revenue account and Income Before Tax. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Standard Biotools' Cost Of Revenue and Income Before Tax is -0.68. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Standard Biotools, assuming nothing else is changed. The correlation between historical values of Standard Biotools' Cost Of Revenue and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Standard Biotools are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Cost Of Revenue i.e., Standard Biotools' Cost Of Revenue and Income Before Tax go up and down completely randomly.

Correlation Coefficient

-0.68

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Standard Biotools income statement and represents the costs associated with goods and services Standard Biotools provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Standard Biotools income statement and is an important metric when analyzing Standard Biotools profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most indicators from Standard Biotools' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Standard Biotools current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.At present, Standard Biotools' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 102.8 M, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.

	2021	2022	2023	2024 (projected)
Interest Expense	3.8M	4.3M	4.6M	4.5M
Depreciation And Amortization	23.2M	15.0M	15.2M	10.8M

Interest Expense Depreciation And Amortization

Standard Biotools fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Good Will
Total Assets		0.39	0.72	0.36	0.28	0.46	0.79	0.7	-0.55	0.62	0.38	0.95	0.44	0.59	0.86	0.51	0.4	0.68	0.89	0.66	0.73	0.77	0.76	0.05	0.49	0.07
Short Long Term Debt Total	0.39		0.41	-0.15	0.24	-0.22	0.05	0.44	0.15	-0.12	0.31	0.35	0.59	0.31	0.34	-0.21	0.12	0.23	0.25	-0.02	0.06	0.18	0.34	-0.28	-0.23	-0.2
Other Current Liab	0.72	0.41		0.41	0.49	0.32	0.66	0.49	-0.46	0.48	0.54	0.74	0.44	0.27	0.74	0.43	-0.1	0.25	0.66	0.34	0.66	0.35	0.44	0.09	0.44	0.07
Total Current Liabilities	0.36	-0.15	0.41		0.48	0.75	0.46	0.1	-0.86	0.57	0.2	0.32	-0.13	0.23	0.37	0.79	0.15	-0.1	0.5	0.32	0.52	0.23	0.33	0.93	0.8	0.8
Total Stockholder Equity	0.28	0.24	0.49	0.48		0.18	0.18	0.16	-0.27	0.4	-0.13	0.3	0.19	0.01	0.61	0.37	0.13	-0.49	0.26	0.3	0.35	-0.33	0.14	0.38	0.35	0.3
Property Plant And Equipment Net	0.46	-0.22	0.32	0.75	0.18		0.7	0.02	-0.87	0.83	0.27	0.42	-0.23	0.24	0.44	0.89	0.09	0.21	0.7	0.56	0.71	0.44	0.38	0.59	0.88	0.65
Current Deferred Revenue	0.79	0.05	0.66	0.46	0.18	0.7		0.42	-0.77	0.81	0.42	0.81	0.26	0.27	0.7	0.78	0.0	0.53	0.89	0.75	0.93	0.64	0.48	0.13	0.78	0.19
Net Debt	0.7	0.44	0.49	0.1	0.16	0.02	0.42		-0.09	0.18	-0.07	0.82	0.71	0.07	0.51	0.0	0.13	0.55	0.57	0.36	0.21	0.57	0.22	-0.11	-0.02	-0.07
Retained Earnings	-0.55	0.15	-0.46	-0.86	-0.27	-0.87	-0.77	-0.09		-0.74	-0.41	-0.48	0.08	-0.39	-0.47	-0.96	-0.16	-0.22	-0.71	-0.54	-0.82	-0.49	-0.51	-0.68	-0.96	-0.64
Accounts Payable	0.62	-0.12	0.48	0.57	0.4	0.83	0.81	0.18	-0.74		0.12	0.6	-0.08	0.25	0.71	0.83	0.21	0.18	0.8	0.75	0.86	0.33	0.45	0.33	0.8	0.28
Cash	0.38	0.31	0.54	0.2	-0.13	0.27	0.42	-0.07	-0.41	0.12		0.25	0.04	0.55	0.25	0.31	-0.12	0.42	0.3	0.0	0.44	0.46	0.54	0.03	0.36	0.09
Non Current Assets Total	0.95	0.35	0.74	0.32	0.3	0.42	0.81	0.82	-0.48	0.6	0.25		0.54	0.31	0.83	0.46	0.18	0.63	0.87	0.66	0.69	0.71	0.52	-0.01	0.44	0.06
Non Currrent Assets Other	0.44	0.59	0.44	-0.13	0.19	-0.23	0.26	0.71	0.08	-0.08	0.04	0.54		-0.02	0.43	-0.13	-0.06	0.33	0.36	0.35	0.11	0.29	0.11	-0.32	-0.15	-0.17
Cash And Short Term Investments	0.59	0.31	0.27	0.23	0.01	0.24	0.27	0.07	-0.39	0.25	0.55	0.31	-0.02		0.42	0.29	0.76	0.5	0.41	0.24	0.4	0.56	0.96	0.16	0.27	0.04
Net Receivables	0.86	0.34	0.74	0.37	0.61	0.44	0.7	0.51	-0.47	0.71	0.25	0.83	0.43	0.42		0.54	0.31	0.31	0.78	0.76	0.73	0.41	0.63	0.07	0.51	0.11
Common Stock Shares Outstanding	0.51	-0.21	0.43	0.79	0.37	0.89	0.78	0.0	-0.96	0.83	0.31	0.46	-0.13	0.29	0.54		0.13	0.12	0.69	0.63	0.85	0.37	0.44	0.59	0.99	0.63
Short Term Investments	0.4	0.12	-0.1	0.15	0.13	0.09	0.0	0.13	-0.16	0.21	-0.12	0.18	-0.06	0.76	0.31	0.13		0.27	0.25	0.29	0.13	0.31	0.73	0.2	0.07	0.02
Non Current Liabilities Total	0.68	0.23	0.25	-0.1	-0.49	0.21	0.53	0.55	-0.22	0.18	0.42	0.63	0.33	0.5	0.31	0.12	0.27		0.56	0.37	0.33	0.94	0.56	-0.3	0.12	-0.14
Inventory	0.89	0.25	0.66	0.5	0.26	0.7	0.89	0.57	-0.71	0.8	0.3	0.87	0.36	0.41	0.78	0.69	0.25	0.56		0.73	0.85	0.68	0.62	0.2	0.66	0.19
Other Current Assets	0.66	-0.02	0.34	0.32	0.3	0.56	0.75	0.36	-0.54	0.75	0.0	0.66	0.35	0.24	0.76	0.63	0.29	0.37	0.73		0.7	0.45	0.45	0.08	0.59	0.18
Other Stockholder Equity	0.73	0.06	0.66	0.52	0.35	0.71	0.93	0.21	-0.82	0.86	0.44	0.69	0.11	0.4	0.73	0.85	0.13	0.33	0.85	0.7		0.46	0.58	0.22	0.84	0.18
Total Liab	0.77	0.18	0.35	0.23	-0.33	0.44	0.64	0.57	-0.49	0.33	0.46	0.71	0.29	0.56	0.41	0.37	0.31	0.94	0.68	0.45	0.46		0.63	0.01	0.37	0.16
Total Current Assets	0.76	0.34	0.44	0.33	0.14	0.38	0.48	0.22	-0.51	0.45	0.54	0.52	0.11	0.96	0.63	0.44	0.73	0.56	0.62	0.45	0.58	0.63		0.17	0.42	0.08
Short Term Debt	0.05	-0.28	0.09	0.93	0.38	0.59	0.13	-0.11	-0.68	0.33	0.03	-0.01	-0.32	0.16	0.07	0.59	0.2	-0.3	0.2	0.08	0.22	0.01	0.17		0.61	0.79
Common Stock	0.49	-0.23	0.44	0.8	0.35	0.88	0.78	-0.02	-0.96	0.8	0.36	0.44	-0.15	0.27	0.51	0.99	0.07	0.12	0.66	0.59	0.84	0.37	0.42	0.61		0.64
Good Will	0.07	-0.2	0.07	0.8	0.3	0.65	0.19	-0.07	-0.64	0.28	0.09	0.06	-0.17	0.04	0.11	0.63	0.02	-0.14	0.19	0.18	0.18	0.16	0.08	0.79	0.64

Click cells to compare fundamentals

Standard Biotools Account Relationship Matchups

Standard Biotools fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	264.8M	324.8M	275.2M	390.3M	323.1M	228.8M
Short Long Term Debt Total	60.0M	95.4M	111.6M	102.7M	98.2M	104.4M
Other Current Liab	12.7M	25.6M	12.2M	10.5M	19.3M	12.6M
Total Current Liabilities	32.8M	54.2M	49.6M	43.4M	109.3M	114.8M
Total Stockholder Equity	153.6M	139.1M	94.6M	(81.5M)	163.2M	171.4M
Property Plant And Equipment Net	12.9M	55.6M	65.2M	59.5M	54.9M	57.6M
Current Deferred Revenue	11.8M	13.5M	15.5M	14.4M	11.6M	7.8M
Net Debt	38.3M	26.9M	83.2M	21.3M	46.5M	49.6M
Retained Earnings	(623.6M)	(676.8M)	(736.0M)	(926.1M)	(1.0B)	(950.7M)
Accounts Payable	6.5M	9.2M	10.6M	7.9M	9.2M	5.5M
Cash	21.7M	68.5M	28.5M	81.3M	51.7M	43.2M
Non Current Assets Total	168.7M	207.1M	203.1M	181.5M	164.9M	124.5M
Non Currrent Assets Other	5.5M	4.7M	3.7M	3.1M	2.3M	4.4M
Cash And Short Term Investments	58.6M	68.5M	28.5M	165.8M	114.9M	72.5M
Net Receivables	19.0M	25.4M	18.3M	17.3M	19.7M	15.4M
Common Stock Shares Outstanding	66.8M	72.0M	75.8M	78.3M	79.2M	83.1M
Short Term Investments	5.1M	0.0	37.0M	84.5M	63.2M	35.1M
Liabilities And Stockholders Equity	264.8M	324.8M	275.2M	390.3M	323.1M	228.8M
Non Current Liabilities Total	78.4M	131.5M	131.1M	428.3M	50.5M	48.0M
Inventory	13.9M	19.7M	20.8M	21.5M	20.5M	13.6M
Other Current Assets	4.6M	4.0M	4.5M	4.3M	3.1M	2.8M
Other Stockholder Equity	777.8M	815.6M	831.4M	846.4M	854.8M	467.6M
Total Liab	111.2M	185.7M	180.6M	471.8M	159.9M	205.2M
Total Current Assets	96.1M	117.7M	72.1M	208.8M	158.2M	104.3M
Accumulated Other Comprehensive Income	(582K)	112K	(907K)	(1.9M)	(2.2M)	(2.1M)
Short Term Debt	1.8M	5.9M	9.9M	9.4M	68.2M	71.6M
Common Stock	70K	75K	77K	80K	83K	87.2K
Intangible Assets	46.2M	40.2M	27.9M	12.6M	1.4M	1.3M
Other Assets	2.6M	2.7M	2.4M	3.1M	2.8M	3.4M
Long Term Debt	53.8M	54.2M	64.2M	62.8M	4.0M	3.8M
Long Term Debt Total	53.8M	54.2M	64.2M	62.8M	56.5M	91.1M
Capital Surpluse	777.8M	815.6M	831.4M	847.0M	974.1M	774.5M
Cash And Equivalents	5.0M	20.7M	28.5M	81.3M	93.5M	98.2M
Property Plant Equipment	12.9M	55.6M	65.2M	59.5M	68.5M	36.3M
Other Liab	20.2M	39.1M	29.3M	20.2M	23.2M	28.7M
Net Tangible Assets	372K	(9.7M)	(41.0M)	110.9M	127.6M	134.0M
Net Invested Capital	207.4M	193.3M	165.6M	(16.6M)	(84.5M)	(80.3M)
Capital Stock	70K	75K	77K	(81.5M)	83K	87.2K
Non Current Liabilities Other	573K	1.3M	882K	961K	1.1M	888.5K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:

How To Invest In Standard

Details

Is Standard Stock a good investment?

Details

What is Standard Biotools' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.

You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.69)

Revenue Per Share

0.558

Quarterly Revenue Growth

(0.14)

Return On Assets

(0.15)

Return On Equity

(0.37)

The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Standard Cost Of Revenue vs Income Before Tax Analysis

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Income Before Tax

Standard Biotools fundamental ratios Correlations

Standard Biotools Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Standard Biotools fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 0.99	Common Stock Shares Outstanding
Total Current Assets	+ 0.96	Cash And Short Term Investments
Non Current Assets Total	+ 0.95	Total Assets
Total Liab	+ 0.94	Non Current Liabilities Total
Short Term Debt	+ 0.93	Total Current Liabilities
Other Stockholder Equity	+ 0.93	Current Deferred Revenue

Common Stock	- 0.96	Retained Earnings
Common Stock Shares Outstanding	- 0.96	Retained Earnings
Retained Earnings	- 0.87	Property Plant And Equipment Net
Retained Earnings	- 0.86	Total Current Liabilities
Other Stockholder Equity	- 0.82	Retained Earnings
Retained Earnings	- 0.77	Current Deferred Revenue